These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22715506)

  • 1. Europe to boost development of new antimicrobial drugs.
    Kirby T
    Lancet; 2012 Jun; 379(9833):2229-30. PubMed ID: 22715506
    [No Abstract]   [Full Text] [Related]  

  • 2. Call for the creation of an international panel on antimicrobial resistance.
    Vet Rec; 2014 May; 174(22):541. PubMed ID: 24920704
    [No Abstract]   [Full Text] [Related]  

  • 3. Policy: An intergovernmental panel on antimicrobial resistance.
    Woolhouse M; Farrar J
    Nature; 2014 May; 509(7502):555-7. PubMed ID: 24877180
    [No Abstract]   [Full Text] [Related]  

  • 4. Ensuring Sustainability of Needed Antibiotics: Aiming for the DART Board.
    Spellberg B; Nielsen TB; Gilbert DN; Shorr AF; Brass EP
    Ann Intern Med; 2019 Oct; 171(8):580-582. PubMed ID: 31590184
    [No Abstract]   [Full Text] [Related]  

  • 5. Stoking the antibiotic pipeline.
    Morel CM; Mossialos E
    BMJ; 2010 May; 340():c2115. PubMed ID: 20483950
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug development: Time for teamwork.
    May M
    Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract]   [Full Text] [Related]  

  • 7. Meeting the challenge of antibiotic resistance.
    Cars O; Högberg LD; Murray M; Nordberg O; Sivaraman S; Lundborg CS; So AD; Tomson G
    BMJ; 2008 Sep; 337():a1438. PubMed ID: 18801866
    [No Abstract]   [Full Text] [Related]  

  • 8. [New antibiotics for the clinical setting, an overview].
    Meylan S; Portillo Tunon V; Guery B
    Rev Med Suisse; 2020 Apr; 16(690):713-718. PubMed ID: 32301304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forging a new path. New law offers incentives to develop antibiotics.
    Lee J
    Mod Healthc; 2013 Feb; 43(5):8-9. PubMed ID: 23437480
    [No Abstract]   [Full Text] [Related]  

  • 10. Switching antibiotics to pharmacy sale will increase resistance, doctors say.
    Hitchen L
    BMJ; 2008 Sep; 337():a1538. PubMed ID: 18765454
    [No Abstract]   [Full Text] [Related]  

  • 11. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.
    Kostyanev T; Bonten MJ; O'Brien S; Steel H; Ross S; François B; Tacconelli E; Winterhalter M; Stavenger RA; Karlén A; Harbarth S; Hackett J; Jafri HS; Vuong C; MacGowan A; Witschi A; Angyalosi G; Elborn JS; deWinter R; Goossens H
    J Antimicrob Chemother; 2016 Feb; 71(2):290-5. PubMed ID: 26568581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time for a change: addressing R&D and commercialization challenges for antibacterials.
    Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: innovation policy for a new era.
    Kapczynski A
    J Law Med Ethics; 2009; 37(2):264-8. PubMed ID: 19493071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving antibiotic markets for long-term sustainability.
    Kesselheim AS; Outterson K
    Yale J Health Policy Law Ethics; 2011; 11(1):101-67. PubMed ID: 21381513
    [No Abstract]   [Full Text] [Related]  

  • 15. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of funding could undermine UK antibiotic resistance strategy, say experts.
    O'Dowd A
    BMJ; 2013 Dec; 347():f7618. PubMed ID: 24355390
    [No Abstract]   [Full Text] [Related]  

  • 17. Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway.
    Årdal C; Johnsen J; Johansen K
    J Law Med Ethics; 2018 Jun; 46(1_suppl):43-49. PubMed ID: 30146956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development.
    Aiello AE; King NB; Foxman B
    Am J Public Health; 2006 Nov; 96(11):1910-4. PubMed ID: 17018817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of a Market Entry Reward within the United States.
    Daniel GW; Schneider M; Lopez MH; McClellan MB
    J Law Med Ethics; 2018 Jun; 46(1_suppl):50-58. PubMed ID: 30146957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperative development of antimicrobials: looking back to look ahead.
    Nathan C
    Nat Rev Microbiol; 2015 Oct; 13(10):651-7. PubMed ID: 26373373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.